Are BGLC insiders buying or selling?

In the last 90 days, BioNexus (BGLC) had 0 insider transactions. Track every executive trade, dollar amount, and date.

Which hedge funds own BGLC?

See every hedge fund and asset manager holding BioNexus (BGLC).

How much of BGLC trades in dark pools?

Track BioNexus (BGLC) dark pool activity and off-exchange block trades.

BioNexus (BGLC) — 67.6% Short — Squeeze Watch

$2.10

+0.01 (+0.48%)

Weekly Expected Move ±4.6%

$2 $2 $2 $2 $2

NASDAQ · Healthcare · Medical - Diagnostics & Research · Alpha Radar Neutral · Power 40 · $3.9M mcap · 1M float · 0.462% daily turnover · Short 52% of daily vol

Overview Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Analysis Technicals Weather Peers ESG Institutions Dark Pool Short Interest Supply Chain

Smart Money Score

No convergence signal

Key Statistics

Market Cap$3.9M

52W Range1.92-15.6

Volume8,470

Avg Volume5,529

Beta2.19

Dividend—

Analyst Ratings

No analyst coverage

Company Info

CEOSu-Leng Tan

Employees30

SectorHealthcare

IndustryMedical - Diagnostics & Research

IPO Date2021-01-08

Websitebionexusgenelab.com

Tower B, Vertical Business Suite
Kuala Lumpur 59200
MY

60 1 2212 6512

About BioNexus Gene Lab Corp.

BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Latest News